Global private equity and venture capital news and research

NEA nets first European biopharma deal with €23m Prosensa investment

25 Jan 2012

New Enterprise Associates has led a €23m financing round for Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, marking the firm’s first biopharmaceutical investment in Europe.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016